

Australian Shareholders' Association

Company	Australian Pharmaceutical Industries
Code	ΑΡΙ
Meeting	AGM
Date	22 January 2020
Venue	Four Seasons Hotel, Sydney
Monitor	Attended by Pamela Murray-Jones for Stewart Burn

Number attendees at meeting	100 including 44 guests
Number of holdings represented by ASA	33
Value of proxies	\$748,322
Number of shares represented by ASA	554,312
Market capitalisation	\$665.09m
Were proxies voted?	Yes, on a poll
Pre AGM Meeting?	Yes, with Mark Smith, Chair

No thrills at this uneventful AGM

There was not even a little pink and silver cardboard handbag and Priceline gift card, as there was last year, to thrill the shareholders at this year's AGM. This was the first to be held in the city after moving from its customary venue at Parramatta.

With the share price hovering round \$1.35 (around where it was in the same month in 2008) shareholders may be hoping the director recruited to replace Gerard Masters, who retired from the Board at the end of the AGM, brings some innovative thinking and renewed energy.

After the withdrawal from the Sigma merger the Board seems fresh out of ideas. While Chair Mark Smith stressed API's growth did not depend on the Sigma merger, when ASA questioned him on possible future growth opportunities, he pointed to organic growth with the Sisterhood loyalty program, gradual growth in the wholesale business, and Clear Skincare clinics.

The CEO gave a thorough briefing on the current position of the company, warning this quarter is expected to be softer because of subdued trading over the Christmas period. He noted challenges in the retail sector due to changes in purchasing habits but was upbeat when questioned on the impact of Amazon's current bid to enter the pharmaceutical market. He noted API had been delivering within 24 hours "forever" and drew attention to the new click-and-collect program supplementing the geographical spread of their pharmacies which gave API a natural advantage.

How closures to the Newcastle and Canberra distribution centres may affect this (if at all) was not mentioned.

Mr Gunderson-Briggs spoke to his election by providing his perspective on the core role of a director: "strategy, risk and solvency". It was interesting he did not mention compliance nor governance, two key duties of directors, perhaps reflecting his experience on the other Board on which he sits, Harvey Norman. When questioned whether he intended to build his shareholding which remains below the ASA recommendation of equivalent to one year's director's fees, he defended his position based on the small windows of opportunity a director has to trade, but confirmed he intended to add to his holding.

All resolutions were carried.